T-Cell Receptor-Like Antibodies: Targeting the Intracellular Proteome Therapeutic Potential and Clinical Applications
Major histocompatibility complex (MHC) class I molecules are key in the immune response against malignant cells by shaping the T-cell repertoire and presenting peptides from endogenous antigens to CD8+ cytotoxic T cells. Because of their unique specificity, MHC-peptide complexes are a desirable targ...
Main Authors: | , |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2013-09-01
|
Series: | Antibodies |
Subjects: | |
Online Access: | http://www.mdpi.com/2073-4468/2/3/517 |
id |
doaj-77ccf9a312bf454ba86cc4467e05f6c2 |
---|---|
record_format |
Article |
spelling |
doaj-77ccf9a312bf454ba86cc4467e05f6c22020-11-24T22:26:06ZengMDPI AGAntibodies2073-44682013-09-012351753410.3390/antib2030517T-Cell Receptor-Like Antibodies: Targeting the Intracellular Proteome Therapeutic Potential and Clinical ApplicationsMaya CohenYoram ReiterMajor histocompatibility complex (MHC) class I molecules are key in the immune response against malignant cells by shaping the T-cell repertoire and presenting peptides from endogenous antigens to CD8+ cytotoxic T cells. Because of their unique specificity, MHC-peptide complexes are a desirable target for novel immunotherapeutic approaches. These complexes can be targeted by recombinant T-cell receptors (TCRs). However, most TCRs produced thus far have affinities which are too low for target detection under normal assay conditions, and limited stability (due to their generation in a single-chain version). Developing high-affinity soluble antibody molecules endowed with a TCR-like specificity toward tumor epitopes, termed TCR-like antibodies, addresses the low affinity of TCRs. These TCR-like antibodies are being developed as a new immunotherapeutic class for targeting tumor cells and mediating their specific killing. In addition, these antibodies are valuable research reagents enabling the study of human class I peptide-MHC ligand-presentation and TCR–peptide–MHC interactions.http://www.mdpi.com/2073-4468/2/3/517antibodiesantibody engineeringimmunotoxinsMHC-peptide complexphage displayrecombinant antibodiesT-cell receptorcancer immunotherapy |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Maya Cohen Yoram Reiter |
spellingShingle |
Maya Cohen Yoram Reiter T-Cell Receptor-Like Antibodies: Targeting the Intracellular Proteome Therapeutic Potential and Clinical Applications Antibodies antibodies antibody engineering immunotoxins MHC-peptide complex phage display recombinant antibodies T-cell receptor cancer immunotherapy |
author_facet |
Maya Cohen Yoram Reiter |
author_sort |
Maya Cohen |
title |
T-Cell Receptor-Like Antibodies: Targeting the Intracellular Proteome Therapeutic Potential and Clinical Applications |
title_short |
T-Cell Receptor-Like Antibodies: Targeting the Intracellular Proteome Therapeutic Potential and Clinical Applications |
title_full |
T-Cell Receptor-Like Antibodies: Targeting the Intracellular Proteome Therapeutic Potential and Clinical Applications |
title_fullStr |
T-Cell Receptor-Like Antibodies: Targeting the Intracellular Proteome Therapeutic Potential and Clinical Applications |
title_full_unstemmed |
T-Cell Receptor-Like Antibodies: Targeting the Intracellular Proteome Therapeutic Potential and Clinical Applications |
title_sort |
t-cell receptor-like antibodies: targeting the intracellular proteome therapeutic potential and clinical applications |
publisher |
MDPI AG |
series |
Antibodies |
issn |
2073-4468 |
publishDate |
2013-09-01 |
description |
Major histocompatibility complex (MHC) class I molecules are key in the immune response against malignant cells by shaping the T-cell repertoire and presenting peptides from endogenous antigens to CD8+ cytotoxic T cells. Because of their unique specificity, MHC-peptide complexes are a desirable target for novel immunotherapeutic approaches. These complexes can be targeted by recombinant T-cell receptors (TCRs). However, most TCRs produced thus far have affinities which are too low for target detection under normal assay conditions, and limited stability (due to their generation in a single-chain version). Developing high-affinity soluble antibody molecules endowed with a TCR-like specificity toward tumor epitopes, termed TCR-like antibodies, addresses the low affinity of TCRs. These TCR-like antibodies are being developed as a new immunotherapeutic class for targeting tumor cells and mediating their specific killing. In addition, these antibodies are valuable research reagents enabling the study of human class I peptide-MHC ligand-presentation and TCR–peptide–MHC interactions. |
topic |
antibodies antibody engineering immunotoxins MHC-peptide complex phage display recombinant antibodies T-cell receptor cancer immunotherapy |
url |
http://www.mdpi.com/2073-4468/2/3/517 |
work_keys_str_mv |
AT mayacohen tcellreceptorlikeantibodiestargetingtheintracellularproteometherapeuticpotentialandclinicalapplications AT yoramreiter tcellreceptorlikeantibodiestargetingtheintracellularproteometherapeuticpotentialandclinicalapplications |
_version_ |
1725754620016328704 |